Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EO-3021 |
Synonyms | |
Therapy Description |
EO-3021 is an antibody-drug conjugate (ADC) comprising an antibody targeting CLDN18.2 linked to monomethyl auristatin E, which potentially induces apoptosis in tumor cells and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): ND11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EO-3021 | EO 3021|EO3021 | CLDN18.2 Antibody 19 | EO-3021 is an antibody-drug conjugate (ADC) comprising an antibody targeting CLDN18.2 linked to monomethyl auristatin E, which potentially induces apoptosis in tumor cells and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): ND11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05980416 | Phase I | EO-3021 | Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Recruiting | USA | 2 |